Stapokibart not checked
Keymed Biosciences Co.Ltd · CM310 · IL-4Rα monoclonal antibody
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
- Tested for
- Atopic Dermatitis (3 trials), Seasonal Allergic Rhinitis (SAR) (2 trials), Bullous Pemphigoid (BP), Chronic Obstructive Pulmonary Disease, Moderate to Severe Asthma
- Main trialPhase 3
- “This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, Pharmacokinetics(PK), PharmacoDynamics(PD) and immunogenicity of Stapokibatrt in children with moderate-to-severe atopic dermatitis.”In the company’s words, NCT06956196 on ClinicalTrials.gov
- Other names
- Stapokibatrt · CM310 · IL-4Rα monoclonal antibody
Other drugs for Atopic Dermatitis
Coming up5
- DecPhase 3 trial completes · ClinicalTrials.gov
- Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- 27 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
- 29 Apr 2032Phase 2/3 trial completes · ClinicalTrials.gov
- May 2032Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials30
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | May 2026 | Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | |
| Phase 3Active, not recruiting | 30 Aug 2026 | Study of CM310 in Adolescent Subjects With Atopic Dermatis | |
| Phase 3Recruiting | Dec 2026 | Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis | |
| Phase 3Not yet recruiting | Feb 2027 | A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | |
| Phase 3Not yet recruiting | 27 Mar 2028 | Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid | |
| Phase 2/3Not yet recruiting | 29 Apr 2032 | A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease | |
| Phase 2/3Recruiting | May 2032 | A Study of CM310 in Subjects With Moderate to Severe Asthma | |
| Phase 2Not yet recruiting | Oct 2026 | Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) | |
| Phase 3Completed | 31 Oct 2023 | A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis | |
| Phase 3Completed | 4 Dec 2023 | Study of CM310 in Subjects With Allergic Rhinitis | |
| Phase 3Completed | 25 Jun 2024 | A Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-2) | |
| Phase 3Completed | 23 Jan 2025 | Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis | |
| Phase 3Completed | 11 Feb 2026 | Study on the Treatment of Prurigo Nodularis With Stapokibart Injection | |
| Phase 2Completed | 8 Nov 2021 | Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) | |
| Phase 2Completed | 18 Mar 2022 | Subcutaneously CM310/Placebo in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CROWNS-1) | |
| Phase 2Completed | 3 Feb 2023 | The Study of CM310 in Patients With Atopic Dermatitis | |
| Phase 2Completed | 28 Jul 2023 | A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis | |
| Phase 2Completed | 13 Sep 2023 | A Study of CM310 in Subjects With Moderate to Severe Asthma | |
| Phase 2Completed | 10 Dec 2023 | Study of CM310 in Patients With Allergic Rhinitis | |
| Phase 2Completed | 31 Jan 2024 | The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps | |
| Phase 2Unknown | 1 Mar 2024 | A Study of CM310 in Subjects With Chronic Pruritus | |
| Phase 2Completed | 18 Jul 2024 | Study of CM310 Injection in Subjects With Moderate-to-Severe Atopic Dermatitis | |
| Phase 2Unknown | 30 Mar 2025 | Study of CM310 in Subjects With Seasonal Allergic Rhinitis | |
| Phase 2Unknown | 30 Oct 2025 | Study of Stapokibart Injection in Patients With Allergic Rhinitis | |
| Phase 2Completed | 26 Nov 2025 | A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis | |
| Phase 1/2Completed | 22 Jan 2021 | Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD) | |
| Phase 1/2Completed | 4 Jul 2024 | Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis | |
| Phase 1Completed | 13 Jan 2020 | Study of CM310 in Healthy Subjects | |
| Phase 1Completed | 26 Jul 2023 | Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310 | |
| Phase 1Unknown | 30 Apr 2025 | Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026